Peter Rossing

Peter Rossing

Clinical Professor

Member of:

  • Internal Medicine: Endocrinology

ORCID: 0000-0002-1531-4294

Publication year:
All
176 - 200 out of 509Page size: 25
Sort by: Title
  1. Published

    Effects of Dapagliflozin in Chronic Kidney Disease, With and Without Other Cardiovascular Medications: DAPA-CKD Trial

    Chertow, G. M., Correa-Rotter, R., Vart, P., Jongs, N., McMurray, J. J. V., Rossing, Peter, Langkilde, A. M., Sjöström, C. D., Toto, R. D., Wheeler, D. C., Heerspink, H. J. L. & Dapa-Ckd Trial Committees Investigators, D. T. C. I., 2023, In: Journal of the American Heart Association. 12, 9, 22 p., e028739.

    Research output: Contribution to journal › Journal article › Research › peer-review

  2. Published

    Effects of Dapagliflozin in Patients With Kidney Disease, With and Without Heart Failure

    McMurray, J. J. V., Wheeler, D. C., Stefánsson, B. V., Jongs, N., Postmus, D., Correa-Rotter, R., Chertow, G. M., Hou, F. F., Rossing, Peter, Sjöström, C. D., Solomon, S. D., Toto, R. D., Langkilde, A. M., Heerspink, H. J. L. & DAPA-CKD Trial Committees and Investigators, D. T. C. A. I., 2021, In: JACC: Heart Failure. 9, 11, p. 807-820 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  3. Published

    Effects of Dapagliflozin in People without Diabetes and with Microalbuminuria

    Heerspink, H. J. L., Chertow, G. M., Jongs, N., Correa-Rotter, R., Rossing, Peter, Sjöström, C. D., Langkilde, A. M. & Wheeler, D. C., 2022, In: Clinical Journal of the American Society of Nephrology. 17, 11, p. 1665-1668 4 p.

    Research output: Contribution to journal › Letter › Research › peer-review

  4. Published

    Effects of Dapagliflozin on EChOcardiographic Measures of CarDiac StructurE and Function in Patients with Chronic Kidney Disease: The DECODE-CKD Trial

    Bartholdy, K. V., Johansen, N. D., Landler, N., Skaarup, K. G., Jensen, J., Bressendorff, I., Schou, Morten, Christensen, J., Feldt-Rasmussen, Bo, Vaduganathan, M., Solomon, S., Haynes, R., Persson, F., Rossing, Peter, Køber, Lars Valeur, Zannad, F., Hansen, Ditte & Biering-Sørensen, Tor, 2023, In: Kidney360. 4, 2, p. 143-149 7 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  5. Published

    Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease: A Post Hoc Analysis of DAPA-CKD

    Schechter, M., Jongs, N., Chertow, G. M., Mosenzon, O., McMurray, J. J. V., Correa-Rotter, R., Rossing, Peter, Langkilde, A. M., Sjöström, C. D., Toto, R. D., Wheeler, D. C. & Heerspink, H. J. L., 2023, In: Annals of Internal Medicine. 176, 1, p. 59-66 8 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  6. Published

    Effects of Dapagliflozin on Volume Status When Added to Renin-Angiotensin System Inhibitors

    Eickhoff, M. K., Dekkers, C. C. J., Kramers, B. J., Laverman, G. D., Frimodt-Møller, M., Jørgensen, Niklas Rye, Faber, Jens, Danser, A. H. J., Gansevoort, R. T., Rossing, Peter, Persson, F. & Heerspink, H. J. L., 31 May 2019, In: Journal of Clinical Medicine. 8, 6

    Research output: Contribution to journal › Journal article › Research › peer-review

  7. Published

    Effects of albuminuria-lowering treatments on inflammation markers: A post hoc analysis from the ROTATE trials

    Sen, T., Curovic, V. R., Jongs, N., Laverman, G. D., Kooy, A., Persson, F., Rossing, Peter & Heerspink, H. J. L., 2023, In: Diabetes, Obesity and Metabolism. 25, 8, p. 2413-2418 6 p.

    Research output: Contribution to journal › Letter › Research › peer-review

  8. Published

    Effects of bardoxolone methyl on body weight, waist circumference and glycemic control in obese patients with type 2 diabetes mellitus and stage 4 chronic kidney disease

    Chertow, G. M., Appel, G. B., Block, G. A., Chin, M. P., Coyne, D. W., Goldsberry, A., Kalantar-Zadeh, K., Meyer, C. J., Molitch, M. E., Pergola, P. E., Raskin, P., Silva, A. L., Spinowitz, B., Sprague, S. M. & Rossing, Peter, 2018, In: Journal of Diabetes and its Complications. 32, 12, p. 1113-1117 5 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  9. Published

    Effects of baricitinib, empagliflozin, linagliptin and telmisartan on cardiovascular autonomic neuropathy in type 1 diabetes: An exploratory, randomized, open-label, crossover trial

    Laursen, J. C., Rotbain Curovic, V., Kroonen, M. Y. A. M., Jongs, N., Zobel, E. H., Hansen, T. W., Frimodt-Møller, M., Laverman, G. D., Kooy, A., Persson, F., Heerspink, H. J. L., Hansen, C. S. & Rossing, Peter, 2023, In: Diabetes, Obesity and Metabolism. 25, 10, p. 3064-3067 4 p.

    Research output: Contribution to journal › Letter › Research › peer-review

  10. Published

    Effects of canagliflozin versus finerenone on cardiorenal outcomes: exploratory post hoc analyses from FIDELIO-DKD compared to reported CREDENCE results

    Agarwal, R., Anker, S. D., Filippatos, G., Pitt, B., Rossing, Peter, Ruilope, L. M., Boletis, J., Toto, R., Umpierrez, G. E., Wanner, C., Wada, T., Scott, C., Joseph, A., Ogbaa, I., Roberts, L., Scheerer, M. F., Bakris, G. L. & FIDELIO-DKD Investigators, F. I., 2022, In: Nephrology Dialysis Transplantation. p. 1261–1269 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  11. Published

    Effects of dapagliflozin in stage 4 chronic kidney disease

    Chertow, G. M., Vart, P., Jongs, N., Toto, R. D., Gorriz, J. L., Hou, F. F., McMurray, J. J. V., Correa-Rotter, R., Rossing, Peter, Sjöström, C. D., Stefánsson, B. V., Langkilde, A. M., Wheeler, D. C. & Heerspink, H. J. L., 2021, In: Journal of the American Society of Nephrology. 32, 9, p. 2352-2361 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  12. Published

    Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

    DAPA-CKD Trial Committees and Investigators, D. T. C. A. I., 2021, In: The Lancet Diabetes and Endocrinology. 9, 1, p. 22-31 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  13. Published

    Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial

    DAPA-CKD Trial Committees and Investigators, D. T. C. A. I., 2021, In: European Heart Journal. 42, 13, p. 1216-1227 12 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  14. Published

    Effects of empagliflozin on myocardial flow reserve in patients with type 2 diabetes mellitus: The simple trial

    Jürgens, M., Schou, Morten, Hasbak, P., Kjær, Andreas, Wolsk, E., Zerahn, B., Wiberg, M., Brandt-Jacobsen, N. H., Gæde, P., Rossing, Peter, Faber, Jens, Inzucchi, S. E., Gustafsson, Finn & Kistorp, Caroline Michaela Nervil, 2021, In: Journal of the American Heart Association. 10, 15, e020418.

    Research output: Contribution to journal › Journal article › Research › peer-review

  15. Published

    Effects of finerenone in people with chronic kidney disease and type 2 diabetes are independent of HbA1c at baseline, HbA1c variability, diabetes duration and insulin use at baseline

    the FIDELIO-DKD and FIGARO-DKD investigators, T. F. A. F. I., 2023, In: Diabetes, Obesity and Metabolism. 25, 6, p. 1512-1522 11 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  16. Published

    Effects of liraglutide on cardiovascular risk biomarkers in patients with type 2 diabetes and albuminuria: A sub-analysis of a randomized, placebo-controlled, double-blind, crossover trial

    von Scholten, B. J., Persson, F., Rosenlund, S., Eugen-Olsen, J., Pielak, T., Faber, Jens, Hansen, T. W. & Rossing, Peter, 2017, In: Diabetes, Obesity and Metabolism. 19, 6, p. 901-905

    Research output: Contribution to journal › Journal article › Research › peer-review

  17. Published

    Effects of once-weekly subcutaneous semaglutide on kidney function and safety in patients with type 2 diabetes: a post-hoc analysis of the SUSTAIN 1–7 randomised controlled trials

    Mann, J. F. E., Hansen, T., Idorn, T., Leiter, L. A., Marso, S. P., Rossing, Peter, Seufert, J., Tadayon, S. & Vilsbøll, Tina, 2020, In: The Lancet Diabetes and Endocrinology. 8, 11, p. 880-893 14 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  18. Published

    Effects of the chymase inhibitor fulacimstat in diabetic kidney disease-results from the CADA DIA trial

    Rossing, Peter, Strand, J., Avogaro, A., Becka, M., Kanefendt, F. & Otto, C., 2021, In: Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association. 36, 12, p. 2263–2273

    Research output: Contribution to journal › Journal article › Research › peer-review

  19. Published

    Effects of two- and twelve-weeks sodium-glucose cotransporter 2 inhibition on DNA and RNA oxidation: two randomized, placebo-controlled trials

    Larsen, E. L., Andersen, A., Kjær, L. K., Eickhoff, M. K., Frimodt-Møller, M., Persson, F., Rossing, Peter, Lykkesfeldt, Jens, Knop, Filip Krag, Vilsbøll, Tina, Rungby, Jørgen & Poulsen, Henrik Enghusen, 2023, In: Free Radical Research. 57, 2, p. 140-151

    Research output: Contribution to journal › Journal article › Research › peer-review

  20. Published

    Efficacy and Safety of Dapagliflozin by Baseline Glycemic Status: A Prespecified Analysis From the DAPA-CKD Trial

    Persson, F., Rossing, Peter, Vart, P., Chertow, G. M., Hou, F. F., Jongs, N., McMurray, J. J., Correa-Rotter, R., Bajaj, H. S., Stefansson, B., Toto, R. D., Langkilde, A. M., Wheeler, D. C., Heerspink, H. J. L. & DAPA-CKD Trial Comm Investigators, D. T. C. I., 2021, In: Diabetes Care. 44, 8, p. 1894-1897 4 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  21. Published

    Efficacy and Safety of Dapagliflozin in Patients With CKD Across Major Geographic Regions

    Vart, P., Correa-Rotter, R., Hou, F. F., Jongs, N., Chertow, G. M., Langkilde, A. M., McMurray, J. J. V., Rossing, Peter, Sjöström, C. D., Stefansson, B. V., Toto, R. D., Douthat, W., Escudero, E., Isidto, R., Khullar, D., Bajaj, H. S., Wheeler, D. C. & Heerspink, H. J. L., 2022, In: Kidney International Reports. 7, 4, p. 699-707 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  22. Published

    Efficacy and Safety of Dapagliflozin in Patients with Chronic Kidney Disease across the Spectrum of Frailty

    Vart, P., Butt, J. H., Jongs, N., Schechter, M., Chertow, G. M., Wheeler, D. C., Pecoits-Filho, R., Langkilde, A. M., Correa-Rotter, R., Rossing, Peter, McMurray, J. J. V. & Heerspink, H. J. L., 2024, In: Journals of Gerontology. Series A: Biological Sciences & Medical Sciences. 79, 2, 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  23. Published

    Efficacy and safety of aldosterone synthase inhibition with and without empagliflozin for chronic kidney disease: a randomised, controlled, phase 2 trial

    Tuttle, K. R., Hauske, S. J., Canziani, M. E., Caramori, M. L., Cherney, D., Cronin, L., Heerspink, H. J. L., Hugo, C., Nangaku, M., Rotter, R. C., Silva, A., Shah, S. V., Sun, Z., Urbach, D., de Zeeuw, D., Rossing, Peter & ASi in CKD group, A. I. C. G., 2024, In: The Lancet. 403, 10424, p. 379-390

    Research output: Contribution to journal › Journal article › Research › peer-review

  24. Published

    Efficacy and safety of finerenone in patients with chronic kidney disease and type 2 diabetes by GLP-1RA treatment: A subgroup analysis from the FIDELIO-DKD trial

    Rossing, Peter, Agarwal, R., Anker, S. D., Filippatos, G., Pitt, B., Ruilope, L. M., Amod, A., Marre, M., Joseph, A., Lage, A., Scott, C., Bakris, G. L. & the FIDELIO-DKD Investigators, T. F. I., 2022, In: Diabetes, Obesity and Metabolism. 24, 1, p. 125-134 10 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

  25. Published

    Efficacy and safety of liraglutide versus placebo as add-on to glucose-lowering therapy in patients with type 2 diabetes and moderate renal impairment (LIRA-RENAL): A randomized clinical trial

    Davies, M. J., Bain, S. C., Atkin, S. L., Rossing, Peter, Scott, D., Shamkhalova, M. S., Bosch-Traberg, H., Syrén, A. & Umpierrez, G. E., Feb 2016, In: Diabetes Care. 39, 2, p. 222-230 9 p.

    Research output: Contribution to journal › Journal article › Research › peer-review

Previous 1...4 5 6 7 8 9 10 11 ...21 Next

ID: 12937790